WallStreetZenWallStreetZen

NYSEMKT: NRXS
Neuraxis Inc Earnings & Revenue

NRXS past revenue growth

How has NRXS's revenue growth performed historically?
Company
-15.37%
Industry
90.7%
Market
19.15%
NRXS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NRXS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

NRXS earnings and revenue history

Current Revenue
$2.3M
Current Earnings
-$14.6M
Current Profit Margin
-633.2%

NRXS Return on Equity

Insufficient data to display

Be the first to know when NRXS announces earnings.

NRXS Return on Assets

Current Company
-1,377.9%
Current Industry
3.2%
NRXS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NRXS Return on Capital Employed

Current Company
495.73%
Current Industry
-42.4%

NRXS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NRXS$2.30M-$14.15M-$14.57M-15.37%N/A
CARA$16.94M-$117.75M-$122.54M-1.04%N/A
MEIP$66.75M$28.01M$26.16M+72.80%N/A
GLYC$10.00k-$36.35M-$37.28M-81.74%N/A
VBIV$9.41M-$74.22M-$83.99M+21.62%N/A

Neuraxis Earnings & Revenue FAQ

What were NRXS's earnings last quarter?

Neuraxis (NYSEMKT: NRXS) reported Q1 2024 earnings per share (EPS) of -$0.32, up 72.88% year over year. Total Neuraxis earnings for the quarter were -$2.12 million. In the same quarter last year, Neuraxis's earnings per share (EPS) was -$1.18.

If you're new to stock investing, here's how to buy Neuraxis stock.

What was NRXS's earnings growth in the past year?

As of Q3 2024, Neuraxis's earnings has grown year over year. Neuraxis's earnings in the past year totalled -$14.57 million.

What was NRXS's revenue last quarter?

Neuraxis (NYSEMKT: NRXS) reported Q1 2024 revenue of $646.64 thousand up 19.68% year over year. In the same quarter last year, Neuraxis's revenue was $805.11 thousand.

What was NRXS's revenue growth in the past year?

As of Q3 2024, Neuraxis's revenue has grown -15.37% year over year. This is 106.07 percentage points lower than the US Biotechnology industry revenue growth rate of 90.7%. Neuraxis's revenue in the past year totalled $2.30 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.